The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) and accounts for 30%to 40%of NHL. Molecules targeting nuclear factor-κB (NF-κB) are expected to be of therapeutic value in those tumors where NF-κB seems to play a unique survival role such as activa...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-05-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558610800545 |
id |
doaj-0121836e261c465bb249f2364f1ad3cc |
---|---|
record_format |
Article |
spelling |
doaj-0121836e261c465bb249f2364f1ad3cc2020-11-25T01:40:08ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022010-05-0112536637510.1593/neo.91960The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In VivoMi-Ae Lyu0Deepak Rai1Kwang Seok Ahn2Bokyung Sung3Lawrence H. Cheung4John W. Marks5Bharat B. Aggarwal6Ricardo C.T. Aguiar7Varsha Gandhi8Michael G. Rosenblum9Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Medicine, The University of Texas Health Science Center, San Antonio, TX, USADepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAImmunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAImmunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Medicine, The University of Texas Health Science Center, San Antonio, TX, USADepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAImmunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) and accounts for 30%to 40%of NHL. Molecules targeting nuclear factor-κB (NF-κB) are expected to be of therapeutic value in those tumors where NF-κB seems to play a unique survival role such as activated B-cell (ABC)-subtype DLBCL. We previously generated a rGel/BLyS fusion toxin for receptor-mediated delivery of the rGel toxin specifically to malignant B cells. In this study, we examined this fusion toxin for its ability to suppress DLBCL growth in vitro and in vivo. rGel/BLyS was specifically cytotoxic to DLBCL lines expressing all three BLyS receptors and constitutively active NF-κB. Treatment with rGel/BLyS induced down-regulation of the phosphorylation of inhibitory subunit of NF-κB (IκB-α), inhibition of NF-κB DNA-binding activity, and accumulation of IκB-α. In agreement with these results, we additionally found that rGel/BLyS downregulated levels of several NF-κB targets including Bcl-xL, Mcl-1, survivin, and x-chromosome linked inhibitor-of-apoptosis. Treatment also induced up-regulation of Bax and apoptosis through caspase-3 activation and poly ADP-ribose polymerase cleavage. Importantly, rGel/BLyS significantly inhibited tumor growth (P < .05) in a DLBCL xenograft model. Thus, our results indicate that rGel/BLyS is an excellent candidate for the treatment of aggressive NHLs that are both dependent on NF-κB and are resistant to conventional chemotherapeutic regimens. http://www.sciencedirect.com/science/article/pii/S1476558610800545 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mi-Ae Lyu Deepak Rai Kwang Seok Ahn Bokyung Sung Lawrence H. Cheung John W. Marks Bharat B. Aggarwal Ricardo C.T. Aguiar Varsha Gandhi Michael G. Rosenblum |
spellingShingle |
Mi-Ae Lyu Deepak Rai Kwang Seok Ahn Bokyung Sung Lawrence H. Cheung John W. Marks Bharat B. Aggarwal Ricardo C.T. Aguiar Varsha Gandhi Michael G. Rosenblum The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo Neoplasia: An International Journal for Oncology Research |
author_facet |
Mi-Ae Lyu Deepak Rai Kwang Seok Ahn Bokyung Sung Lawrence H. Cheung John W. Marks Bharat B. Aggarwal Ricardo C.T. Aguiar Varsha Gandhi Michael G. Rosenblum |
author_sort |
Mi-Ae Lyu |
title |
The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo |
title_short |
The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo |
title_full |
The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo |
title_fullStr |
The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo |
title_full_unstemmed |
The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo |
title_sort |
rgel/blys fusion toxin inhibits diffuse large b-cell lymphoma growth in vitro and in vivo |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 1522-8002 |
publishDate |
2010-05-01 |
description |
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) and accounts for 30%to 40%of NHL. Molecules targeting nuclear factor-κB (NF-κB) are expected to be of therapeutic value in those tumors where NF-κB seems to play a unique survival role such as activated B-cell (ABC)-subtype DLBCL. We previously generated a rGel/BLyS fusion toxin for receptor-mediated delivery of the rGel toxin specifically to malignant B cells. In this study, we examined this fusion toxin for its ability to suppress DLBCL growth in vitro and in vivo. rGel/BLyS was specifically cytotoxic to DLBCL lines expressing all three BLyS receptors and constitutively active NF-κB. Treatment with rGel/BLyS induced down-regulation of the phosphorylation of inhibitory subunit of NF-κB (IκB-α), inhibition of NF-κB DNA-binding activity, and accumulation of IκB-α. In agreement with these results, we additionally found that rGel/BLyS downregulated levels of several NF-κB targets including Bcl-xL, Mcl-1, survivin, and x-chromosome linked inhibitor-of-apoptosis. Treatment also induced up-regulation of Bax and apoptosis through caspase-3 activation and poly ADP-ribose polymerase cleavage. Importantly, rGel/BLyS significantly inhibited tumor growth (P < .05) in a DLBCL xenograft model. Thus, our results indicate that rGel/BLyS is an excellent candidate for the treatment of aggressive NHLs that are both dependent on NF-κB and are resistant to conventional chemotherapeutic regimens.
|
url |
http://www.sciencedirect.com/science/article/pii/S1476558610800545 |
work_keys_str_mv |
AT miaelyu thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT deepakrai thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT kwangseokahn thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT bokyungsung thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT lawrencehcheung thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT johnwmarks thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT bharatbaggarwal thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT ricardoctaguiar thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT varshagandhi thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT michaelgrosenblum thergelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT miaelyu rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT deepakrai rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT kwangseokahn rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT bokyungsung rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT lawrencehcheung rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT johnwmarks rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT bharatbaggarwal rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT ricardoctaguiar rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT varshagandhi rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo AT michaelgrosenblum rgelblysfusiontoxininhibitsdiffuselargebcelllymphomagrowthinvitroandinvivo |
_version_ |
1725046903296491520 |